Jade Montgomery's questions to Soleno Therapeutics Inc (SLNO) leadership • Q2 2025
Question
Jade Montgomery, on behalf of Ram Selvaraju at H.C. Wainwright, asked about any prescriber reluctance to use VICAT XR in PWS patients who also have diabetes, and inquired about future plans for portfolio expansion.
Answer
CEO Anish Bhatnagar explained that while a provider might be hesitant with uncontrolled diabetes, the drug can be used with appropriate monitoring in patients with controlled diabetes. He added that the company is currently 'laser focused' on the VICAT XR launch, but long-term diversification into adjacent therapeutic areas is a possibility.